Butyrate and the brain–gut axis in Parkinson's disease: From microbial metabolite to potential therapeutic target
Journal of International Medical Research · 2026-11 · 54 (11)
DOI: 10.1177/03000605261504876 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of International Medical Research, online erschienen am 18.11.2026. Verfasst von Junjian Hu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Central Laboratory, Dongguan Songshan Lake Central Hospital, Affiliated Hospital of Guangdong Medical University, China. Hauptthemen laut MEDLINE: Parkinson Disease, Butyrates, Gastrointestinal Microbiome, Brain-Gut Axis. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Parkinson's disease is a progressive neurodegenerative disorder with substantial unmet therapeutic needs. This narrative review synthesizes current mechanistic and clinical evidence on the role of the gut microbiota–derived short-chain fatty acid butyrate in the brain–gut axis in Parkinson's disease. Mechanistically, experimental studies suggest that butyrate reinforces intestinal barrier integrity and modulates intestinal immune responses, with enteric glial and vagal pathways providing possible links to central neuroinflammation. Its effects on microglial inflammatory phenotypes and autophagic clearance of α-synuclein, including possible cholinergic mediation, require further validation. We critically evaluated the strengths and limitations of this evidence, discussed inconsistent findings across cohorts, and summarized clinical studies on butyrate-related interventions, including butyrate supplementation, dietary fiber, probiotics, and fecal microbiota transplantation. Although preclinical evidence is substantial and context dependent, clinical translation is constrained by small and heterogeneous human cohorts, unresolved butyrate bioavailability, optimal dose and route of administration, long-term safety concerns, variability of the gut microbiota, and the absence of randomized evidence establishing butyrate-specific disease modification. Microglial heterogeneity revealed by single-cell transcriptomic studies also challenges the classical M1/M2 framework. We conclude by proposing priorities for future research, including well-powered randomized trials, standardized butyrate and microbiome measurements, patient stratification, and single-cell investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Central Laboratory, Dongguan Songshan Lake Central Hospital, Affiliated Hospital of Guangdong Medical University, China.
- Department of Neurology, Dongguan Songshan Lake Central Hospital, Affiliated Hospital of Guangdong Medical University, China.
ORCID-Profile: Yuhan Zhang
Zitieren
APA
Hu, J., & Zhang, Y. (2026). Butyrate and the brain–gut axis in Parkinson's disease: From microbial metabolite to potential therapeutic target. Journal of International Medical Research, 54(11). https://doi.org/10.1177/03000605261504876
Vancouver
Hu J, Zhang Y. Butyrate and the brain–gut axis in Parkinson's disease: From microbial metabolite to potential therapeutic target. Journal of International Medical Research. 2026;54(11). doi:10.1177/03000605261504876
BibTeX
@article{Hu2026,
author = {Hu, Junjian and Zhang, Yuhan},
title = {Butyrate and the brain–gut axis in Parkinson's disease: From microbial metabolite to potential therapeutic target},
journal = {Journal of International Medical Research},
year = {2026},
volume = {54},
number = {11},
doi = {10.1177/03000605261504876}
}
EUVIMED